Brain

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Telerehabilitation Systems Market to Expand by USD 532.9 Million (2024-2028), Rising Chronic Disease Cases Driving Revenue, AI Impacting Market Trends – Technavio

NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global telerehabilitation systems market...

Brooks Rehabilitation, Nemours Children’s Health, Wolfson Children’s Hospital and UF Health Jacksonville Partner to Enhance Pediatric Care

JACKSONVILLE, Fla., Nov. 21, 2024 /PRNewswire/ -- By combining resources and expertise, Brooks Rehabilitation, Nemours Children's Health, Jacksonville, Wolfson Children's...

Aires Tech Showcases Advanced Technology at UFC Performance Institute with “Next Frontier of UFC Training and Performance” Symposium

Symposium gathered top fighters, neuroscientists, and media together in New York City on eve of UFC 309 UFC Performance Institute leader,...

error: Content is protected !!